Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Randomized Double-Blind Placebo-Controlled 3-Period Single-Dose Crossover Study to Evaluate the Safety and Efficacy of Two Doses of AD-109 in Mild to Moderate Obstructive Sleep Apnea

Next Previous
X
Search
Trial Profile

Phase 2 Randomized Double-Blind Placebo-Controlled 3-Period Single-Dose Crossover Study to Evaluate the Safety and Efficacy of Two Doses of AD-109 in Mild to Moderate Obstructive Sleep Apnea

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aroxybutynin/atomoxetine Apnimed (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Therapeutic Use
  • Sponsors Apnimed

    • Most Recent Events

    • 09 Mar 2022 According to an Apnimed media release, Russell Rosenberg is the principal investigator for the study.
    • 09 Mar 2022 According to an Apnimed media release, data from the study will be featured in an oral presentation at World Sleep 2022.
    • 13 Oct 2021 Primary endpoint of Change in Hypoxic Burden has been met, according to an Apnimed media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top